Clinical Laserthermia Systems AB (publ) (CLS-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clinical Laserthermia Systems AB (publ) (CLS-B) has a cash flow conversion efficiency ratio of -0.161x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.69 Million ≈ $-1.15 Million USD) by net assets (Skr66.48 Million ≈ $7.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Clinical Laserthermia Systems AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Clinical Laserthermia Systems AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Clinical Laserthermia Systems AB (publ) carry for a breakdown of total debt and financial obligations.
Clinical Laserthermia Systems AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clinical Laserthermia Systems AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Grob Tea Company Limited
NSE:GROBTEA
|
-0.064x |
|
Telecom Plus PLC
LSE:TEP
|
0.263x |
|
Holand og Setskog Sparebank
OL:HSPG
|
0.251x |
|
Park & Bellheimer AG
F:PKB
|
0.143x |
|
Arcoma AB
ST:ARCOMA
|
-0.004x |
|
Yelooo Integra Datanet Tbk PT
JK:YELO
|
-0.001x |
|
iOThree Limited Ordinary Shares
NASDAQ:IOTR
|
N/A |
|
Cielo Waste Solutions Corp
V:CMC
|
0.452x |
Annual Cash Flow Conversion Efficiency for Clinical Laserthermia Systems AB (publ) (2008–2025)
The table below shows the annual cash flow conversion efficiency of Clinical Laserthermia Systems AB (publ) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Clinical Laserthermia Systems AB (publ) market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr66.48 Million ≈ $7.15 Million |
Skr-33.20 Million ≈ $-3.57 Million |
-0.499x | +41.89% |
| 2024-12-31 | Skr65.69 Million ≈ $7.07 Million |
Skr-56.45 Million ≈ $-6.08 Million |
-0.859x | +43.70% |
| 2023-12-31 | Skr43.53 Million ≈ $4.68 Million |
Skr-66.45 Million ≈ $-7.15 Million |
-1.527x | +83.01% |
| 2022-12-31 | Skr7.87 Million ≈ $846.40K |
Skr-70.69 Million ≈ $-7.61 Million |
-8.988x | -187.72% |
| 2021-12-31 | Skr21.18 Million ≈ $2.28 Million |
Skr-66.17 Million ≈ $-7.12 Million |
-3.124x | +21.47% |
| 2020-12-31 | Skr13.93 Million ≈ $1.50 Million |
Skr-55.41 Million ≈ $-5.96 Million |
-3.978x | +28.85% |
| 2019-12-31 | Skr7.00 Million ≈ $752.99K |
Skr-39.12 Million ≈ $-4.21 Million |
-5.591x | -619.15% |
| 2018-12-31 | Skr49.81 Million ≈ $5.36 Million |
Skr-38.72 Million ≈ $-4.17 Million |
-0.777x | -5.20% |
| 2017-12-31 | Skr33.00 Million ≈ $3.55 Million |
Skr-24.39 Million ≈ $-2.62 Million |
-0.739x | +35.74% |
| 2016-12-31 | Skr17.06 Million ≈ $1.84 Million |
Skr-19.63 Million ≈ $-2.11 Million |
-1.150x | -19.85% |
| 2015-12-31 | Skr19.46 Million ≈ $2.09 Million |
Skr-18.68 Million ≈ $-2.01 Million |
-0.960x | -92.50% |
| 2014-12-31 | Skr31.58 Million ≈ $3.40 Million |
Skr-15.74 Million ≈ $-1.69 Million |
-0.499x | +28.93% |
| 2013-12-31 | Skr26.09 Million ≈ $2.81 Million |
Skr-18.30 Million ≈ $-1.97 Million |
-0.702x | +0.45% |
| 2012-12-31 | Skr17.09 Million ≈ $1.84 Million |
Skr-12.05 Million ≈ $-1.30 Million |
-0.705x | -28.07% |
| 2011-12-31 | Skr10.83 Million ≈ $1.17 Million |
Skr-5.96 Million ≈ $-641.36K |
-0.550x | -15.89% |
| 2010-12-31 | Skr10.36 Million ≈ $1.11 Million |
Skr-4.92 Million ≈ $-529.25K |
-0.475x | -38.16% |
| 2009-12-31 | Skr6.63 Million ≈ $713.34K |
Skr-2.28 Million ≈ $-245.16K |
-0.344x | -1723.94% |
| 2008-12-31 | Skr3.68 Million ≈ $395.79K |
Skr-69.30K ≈ $-7.46K |
-0.019x | -- |
About Clinical Laserthermia Systems AB (publ)
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control trea… Read more